A Combined Lymphokine-activated Killer (LAK) cell immunotherapy and adenovirus-p53 gene therapy for head and neck squamous cell carcinoma

Hiroki Saito; Satoshi Ando; Naoya Morishita; Kyung Mi Lee; Dante Dator; David Dy; Katsumi Shigemura; Zainal Adhim; Ken Ichi Nibu; Masato Fujisawa; Toshiro Shirakawa

A Combined Lymphokine-activated Killer (LAK) cell immunotherapy and adenovirus-p53 gene therapy for head and neck squamous cell carcinoma

Hiroki Saito, Satoshi Ando, Naoya Morishita, Kyung Mi Lee, Dante Dator, David Dy, Katsumi Shigemura, Zainal Adhim, Ken Ichi Nibu, Masato Fujisawa, Toshiro Shirakawa

Melanoma Medical Oncology

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

Background: The antitumor activity of lymphokine activated killer (LAK) cells immunotherapy is not always effective in all patients, especially when used alone. In this study, we investigated the in vitro antitumor activities of a combination of LAK immunotherapy and gene therapy employing an adenovirus carrying the p53 gene (Ad-p53) in human head and neck squamous cell carcinoma. Materials and Methods: The in vitro cytotoxicity of LAK cells was tested in H891 cells infected with or without Ad-p53, and the mRNA expression levels of natural killer group 2D ligands (UL16 binding protein (ULBP) 1 to 5) and tumor necrosis factor (TNF-α) in these cells were measured by real-time reverse transcription polymerase chain reaction. Results: Ad-p53 infection increased the cytotoxicity of LAK cells against H891 cells, and also increased the mRNA expression levels of the ULBPs in H891 cells and TNF-α in the LAK cells. Conclusion: The antitumor activities of LAK cells in H891 cells were enhanced by Ad-p53. Conclusion: The combinational therapy of LAK immunotherapy and Ad-p53 gene therapy may represent a new paradigm for the treatment of head and neck cancer.

Original language	English (US)
Pages (from-to)	3365-3370
Number of pages	6
Journal	Anticancer research
Volume	34
Issue number	7
State	Published - Jul 1 2014

Keywords

Ad-p53 gene therapy
Head neck squamous cell carcinoma
LAK immunotherapy
TNF-a

ASJC Scopus subject areas

Oncology
Cancer Research

Cite this

@article{c37d179eb7ff45df8eda9b748b60a721,

title = "A Combined Lymphokine-activated Killer (LAK) cell immunotherapy and adenovirus-p53 gene therapy for head and neck squamous cell carcinoma",

abstract = "Background: The antitumor activity of lymphokine activated killer (LAK) cells immunotherapy is not always effective in all patients, especially when used alone. In this study, we investigated the in vitro antitumor activities of a combination of LAK immunotherapy and gene therapy employing an adenovirus carrying the p53 gene (Ad-p53) in human head and neck squamous cell carcinoma. Materials and Methods: The in vitro cytotoxicity of LAK cells was tested in H891 cells infected with or without Ad-p53, and the mRNA expression levels of natural killer group 2D ligands (UL16 binding protein (ULBP) 1 to 5) and tumor necrosis factor (TNF-α) in these cells were measured by real-time reverse transcription polymerase chain reaction. Results: Ad-p53 infection increased the cytotoxicity of LAK cells against H891 cells, and also increased the mRNA expression levels of the ULBPs in H891 cells and TNF-α in the LAK cells. Conclusion: The antitumor activities of LAK cells in H891 cells were enhanced by Ad-p53. Conclusion: The combinational therapy of LAK immunotherapy and Ad-p53 gene therapy may represent a new paradigm for the treatment of head and neck cancer.",

keywords = "Ad-p53 gene therapy, Head neck squamous cell carcinoma, LAK immunotherapy, TNF-a",

author = "Hiroki Saito and Satoshi Ando and Naoya Morishita and Lee, {Kyung Mi} and Dante Dator and David Dy and Katsumi Shigemura and Zainal Adhim and Nibu, {Ken Ichi} and Masato Fujisawa and Toshiro Shirakawa",

year = "2014",

month = jul,

day = "1",

language = "English (US)",

volume = "34",

pages = "3365--3370",

journal = "Anticancer research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "7",

}

TY - JOUR

T1 - A Combined Lymphokine-activated Killer (LAK) cell immunotherapy and adenovirus-p53 gene therapy for head and neck squamous cell carcinoma

AU - Saito, Hiroki

AU - Ando, Satoshi

AU - Morishita, Naoya

AU - Lee, Kyung Mi

AU - Dator, Dante

AU - Dy, David

AU - Shigemura, Katsumi

AU - Adhim, Zainal

AU - Nibu, Ken Ichi

AU - Fujisawa, Masato

AU - Shirakawa, Toshiro

PY - 2014/7/1

Y1 - 2014/7/1

N2 - Background: The antitumor activity of lymphokine activated killer (LAK) cells immunotherapy is not always effective in all patients, especially when used alone. In this study, we investigated the in vitro antitumor activities of a combination of LAK immunotherapy and gene therapy employing an adenovirus carrying the p53 gene (Ad-p53) in human head and neck squamous cell carcinoma. Materials and Methods: The in vitro cytotoxicity of LAK cells was tested in H891 cells infected with or without Ad-p53, and the mRNA expression levels of natural killer group 2D ligands (UL16 binding protein (ULBP) 1 to 5) and tumor necrosis factor (TNF-α) in these cells were measured by real-time reverse transcription polymerase chain reaction. Results: Ad-p53 infection increased the cytotoxicity of LAK cells against H891 cells, and also increased the mRNA expression levels of the ULBPs in H891 cells and TNF-α in the LAK cells. Conclusion: The antitumor activities of LAK cells in H891 cells were enhanced by Ad-p53. Conclusion: The combinational therapy of LAK immunotherapy and Ad-p53 gene therapy may represent a new paradigm for the treatment of head and neck cancer.

AB - Background: The antitumor activity of lymphokine activated killer (LAK) cells immunotherapy is not always effective in all patients, especially when used alone. In this study, we investigated the in vitro antitumor activities of a combination of LAK immunotherapy and gene therapy employing an adenovirus carrying the p53 gene (Ad-p53) in human head and neck squamous cell carcinoma. Materials and Methods: The in vitro cytotoxicity of LAK cells was tested in H891 cells infected with or without Ad-p53, and the mRNA expression levels of natural killer group 2D ligands (UL16 binding protein (ULBP) 1 to 5) and tumor necrosis factor (TNF-α) in these cells were measured by real-time reverse transcription polymerase chain reaction. Results: Ad-p53 infection increased the cytotoxicity of LAK cells against H891 cells, and also increased the mRNA expression levels of the ULBPs in H891 cells and TNF-α in the LAK cells. Conclusion: The antitumor activities of LAK cells in H891 cells were enhanced by Ad-p53. Conclusion: The combinational therapy of LAK immunotherapy and Ad-p53 gene therapy may represent a new paradigm for the treatment of head and neck cancer.

KW - Ad-p53 gene therapy

KW - Head neck squamous cell carcinoma

KW - LAK immunotherapy

KW - TNF-a

UR - http://www.scopus.com/inward/record.url?scp=84906343606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906343606&partnerID=8YFLogxK

M3 - Article

C2 - 24982341

AN - SCOPUS:84906343606

SN - 0250-7005

VL - 34

SP - 3365

EP - 3370

JO - Anticancer research

JF - Anticancer research

IS - 7

ER -

A Combined Lymphokine-activated Killer (LAK) cell immunotherapy and adenovirus-p53 gene therapy for head and neck squamous cell carcinoma

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this